文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

产超广谱β-内酰胺酶肠杆菌科定植ICU患者中感染相关呼吸机相关并发症的临床意义

Infection-related ventilator-associated complications in ICU patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae.
PubMed 文献 · Intensive Care Med · 2018-04-16
一句话结论在产超广谱β-内酰胺酶肠杆菌科定植的机械通气患者中,感染相关呼吸机相关并发症多反映非感染性事件,但却是经验性碳青霉烯类消耗的强驱动因素,ESBLE感染仅占7%。

该研究基于法国前瞻性多中心OUTCOMEREA数据库(17个ICU,1997-2015年),纳入318例ESBLE定植且机械通气>48小时、携带状态确认后发生≥1次IVAC的患者。576次IVAC中63%无明确感染,21%为非VAP感染,13%为非ESBLE VAP,3%为ESBLE VAP,ESBLE感染总计仅43次(7%)。前3天碳青霉烯暴露是ESBLE感染作为IVAC病因的唯一独立预测因素,呈保护效应(校正OR 0.2,95%CI 0.05-0.6;P<0.01)。碳青霉烯类启动率从无感染IVAC的9%升至ESBLE VAP的56%(ESBLE VAP vs 非ESBLE VAP:P=0.43)。结论认为ESBLE感染少见且难以预测,亟需新型诊断方法和碳青霉烯节约策略。

要点

  • 在ESBLE定植的机械通气患者中,IVAC大多(63%)无明确感染,仅7%的IVAC由ESBLE感染引起。
  • 前3天碳青霉烯暴露是ESBLE感染作为IVAC病因的唯一独立预测因素,呈保护效应(校正OR 0.2,95%CI 0.05-0.6;P<0.01)。
  • 碳青霉烯类启动率:无感染IVAC为9%,非VAP感染IVAC为15%,非ESBLE VAP为42%,ESBLE VAP为56%(ESBLE VAP vs 非ESBLE VAP:P=0.43)。
  • IVAC在ESBLE定植者中主要反映非感染性事件,但却是经验性碳青霉烯类消耗的强驱动因素。
  • ESBLE感染稀少但难以预测,作者认为亟需新型诊断方法和碳青霉烯节约替代方案。

适用人群与场景

  • 法国17个ICU中ESBLE定植(入ICU时系统性直肠拭子筛查,之后每周和/或尿液或浅表手术部位定植)且机械通气>48小时、携带状态确认后发生≥1次IVAC的患者。
  • 共纳入318例ESBLE携带者,中位年龄68岁,男性67%,内科入院68%,输入性定植53%。

诊断标准与关键阈值

  • ESBLE定植:入ICU时系统性直肠拭子筛查,之后每周和/或尿液或浅表手术部位定植。
  • IVAC:机械通气>48小时且携带状态确认后发生≥1次感染相关呼吸机相关并发症。
  • 所有ICU获得性感染均有微生物学证据。

研究设计与关键结果

  • 研究类型:前瞻性多中心起始队列研究(法国OUTREMEREA数据库,17个ICU,1997-2015年)。
  • 人群:318例ESBLE定植的机械通气患者,共发生576次IVAC。
  • IVAC构成:361次(63%)无明确感染,124次(21%)为非VAP感染,73次(13%)为非ESBLE VAP,18次(3%)为ESBLE VAP;ESBLE感染总计43次(7%)。
  • 前3天碳青霉烯暴露是ESBLE感染作为IVAC病因的唯一独立预测因素,呈保护效应(校正OR 0.2,95%CI 0.05-0.6;P<0.01)。
  • 碳青霉烯类启动率:无感染IVAC为9%,非VAP感染IVAC为15%,非ESBLE VAP为42%,ESBLE VAP为56%(ESBLE VAP vs 非ESBLE VAP:P=0.43)。

证据类型、等级与局限

  • 证据类型:前瞻性多中心起始队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ESBLE定植的机械通气患者中,出现IVAC时不应默认其为ESBLE感染,因为63%的IVAC无明确感染,仅7%由ESBLE感染引起。
  • 前3天碳青霉烯暴露与ESBLE感染作为IVAC病因的风险降低独立相关(校正OR 0.2,95%CI 0.05-0.6),可辅助判断经验性碳青霉烯的必要性。
  • IVAC是经验性碳青霉烯消耗的强驱动因素,碳青霉烯启动率在无感染IVAC中为9%,在ESBLE VAP中为56%。
  • 作者认为ESBLE感染稀少但难以预测,亟需新型诊断方法和碳青霉烯节约替代方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To investigate the clinical significance of infection-related ventilator-associated complications (IVAC) and their impact on carbapenem consumption in mechanically ventilated (MV) patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLE).

METHODS: Inception cohort study from the French prospective multicenter OUTCOMEREA database (17 ICUs, 1997-2015) including all ESBLE carriers (systematic rectal swabbing at admission then weekly and/or urinary or superficial surgical site colonisation) with MV duration > 48 h and ≥ 1 episode of IVAC after carriage documentation. All ICU-acquired infections were microbiologically documented.

RESULTS: The 318 enrolled ESBLE carriers (median age 68 years; males 67%; medical admission 68%; imported carriage 53%) experienced a total of 576 IVAC comprising 361 episodes (63%) without documented infection, 124 (21%) related to infections other than ventilator-associated pneumonia (VAP), 73 (13%) related to non-ESBLE VAP and 18 (3%) related to ESBLE VAP. Overall, ESBLE infections accounted for only 43 episodes (7%). Carbapenem exposure within the preceding 3 days was the sole independent predictor of ESBLE infection as the causative event of IVAC, with a protective effect (adjusted odds ratio 0.2, 95% confidence interval 0.05-0.6; P < 0.01). Carbapenems were initiated in 9% of IVAC without infection, 15% of IVAC related to non-VAP infections, 42% of IVAC related to non-ESBLE VAP, and 56% of IVAC related to ESBLE VAP (ESBLE VAP versus non-ESBLE VAP: P = 0.43).

CONCLUSIONS: IVAC in ESBLE carriers mostly reflect noninfectious events but act as a strong driver of empirical carbapenem consumption. ESBLE infections are scarce yet hard to predict, strengthening the need for novel diagnostic approaches and carbapenem-sparing alternatives.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Barbier F, Bailly S, Schwebel C, et al. Infection-related ventilator-associated complications in ICU patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae. Intensive Care Med. 2018. PMID: 29663045. doi:10.1007/s00134-018-5154-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。